Hosted on MSN11mon
New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding
Milvexian targets the activated, or clot-initiating, form of factor XI, called factor XIa. Harvard’s Gibson is leading one of the trials. Also in the mix is Anthos Therapeutics, a startup ...
pharmaphorum6d
Bayer doubles down on Factor XIa with new phase 3 trial
Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.
pharmaphorum2d
Bayer pulls atrial fibrillation study for asundexian
Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...
Business Wire1mon
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safety CAMBRIDGE, Mass.